USF Health is providing COVID-19 vaccinations to patients, employees and individuals in the community who meet eligibility criteria and as supply of vaccine permits. Learn More.


Request Appointment

(813) 259-8700

Refer a Patient

Current studies and clinical trials

Dr. Tanya Murphy

Title: Av1ation: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 with Autism Spectrum Disorder (ASD)
Purpose/Description: To evaluate the efficacy, safety, and tolerability of an experimental drug RO5285119 compared to placebo.  RO5285119 is a highly selective human V1a receptor antagonist that is shown to modulate social behaviors and is intended to improve social communication and interaction skills.
Type: Medication/Clinical Trial 
Participants: Individuals aged 5-17 with high functioning ASD 
Contact: Kalie Pham via email at or by phone at (727) 767-8393.

Title: T-Force Gold: A Randomized, Double-blind, Placebo-controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects with Tourette Syndrome 
Purpose: To evaluate the efficacy, safety, and tolerability of an experimental drug NBI-98854 (valbenazine tosylate) compared to placebo in children ages 6-17 with Tourette syndrome. NBI-98854 is a selective VMAT2 inhibitor under development for the treatment of TS after being approved by the US Food and Drug Administration (FDA) for treatment of adults with tardive dyskinesia (TD). 
Type: Medication/Clinical Trial 
Participants: Individuals aged 6-17 years with a diagnosis of Tourette Syndrome
Contact: Kalie Pham via email at or by phone at (727) 767-8393.

Title: Shine: A Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-dose Safety and Efficacy Study of SPD489 Compared with Placebo in Preschool Children Aged 4-5 Years with Attention-deficit/Hyperactivity disorder (ADHD) 
Purpose/Description: To evaluate the efficacy of an experimental drug SPD489 (Lisdexamfetamine dimesylate) compared to placebo in preschool children (4-5 years of age) with Attention-deficit/Hyperactivity Disorder (ADHD).  
Type: Medication/Clinical Trial
Participants: Individuals aged 4-5 years with primary diagnosis of ADHD (any subtype) 
Contact: Kalie Pham via email at or by phone at (727) 767-8393.

Title: Tic Treatment Preference:  An Examination of Treatment Preference in Pediatric Tourette and Tic Disorder Population 
Purpose/Description: To examine parent treatment preferences and factors associated with parent treatment preference for children with TS, other chronic tic disorders, and provisional tic disorder using an in-clinic survey administered to parents that are receiving treatment for their child at the Rothman Center.
Type: Non-treatment/ Survey
Participants: Individuals aged 7-17 with motor or phonic tics attending a scheduled appointment t at the Rothman Center 
Contact: Kalie Pham via email at or by phone at (727) 767-8393.

Title: Immune Characterization:  Immune Factors and Psychosocial Correlates in Pediatric Tic Disorders and Obsessive Compulsive Disorder
Purpose/Description: To understand more about immune-related factors that might influence symptoms of tics, anxiety, and OCD in children.  In particular, we are interested in how infections and other immune factors might contribute to increased symptoms in youth with tics, anxiety, or OCD.  Also enrolling healthy controls. 
Type: Non-treatment 
Participants: Individuals aged 4-17 years attending a scheduled appointment at the Rothman Center 
*Healthy controls: Individuals aged 4-17 years with no prior diagnosis of any neuropsychiatric or developmental disorder and not receiving special education services
Contact: Kalie Pham via email at or by phone at (727) 767-8393.

Dr. Adam Lewin

Title: A Brief Behavioral Treatment for Anxiety in Young Children
Purpose: To examine the effectiveness of a parent-led behavioral treatment for children ages 3 to 7 years old with problematic anxiety. 
Contact: Dr. Adam Lewin by phone at (727) 767-8230.

Dr. Omar Rahman

Title: Habit Reversal Training for Trichotillomania in Youth: A Controlled Trial
Purpose: To examine how well habit reversal training (HRT) works in treatment of Trichotillomania in children and adolescents; to examine the how well certain psychosocial factors predict treatment response.
Contact: Dr. Omar Rahman by phone at (727) 767-8230.